Experts warn that U.S. tariffs on pharmaceuticals could harm global health governance.
Sure, I can help with that! However, it seems that your request got cut off. Could you please provide the full article description you'd like me to rewrite?
TroibNews 
U.S. President Donald Trump's remarks regarding the implementation of a new tariff on pharmaceuticals have sparked public concern over drug pricing and the integrity of the global health framework.
"We're going to be announcing very shortly a major tariff on pharmaceuticals," Trump stated on Tuesday during the National Republican Congressional Committee dinner, though he did not provide further details.
Experts caution that the proposed drug tariffs may increase medicine prices and worsen drug shortages, potentially pushing more manufacturers to relocate operations domestically.
Decreased Access to Medications
Industry leaders and drug pricing specialists have expressed that tariffs could heighten the risk of shortages for commonly used, inexpensive generic medications, like antibiotics, which manufacturers argue they might not be able to produce due to elevated costs, according to Reuters.
Additionally, tariffs could diminish the profit margins of expensive brand-name pharmaceuticals and biotech drugs, leading to reduced funds available for research and development of future treatments, as reported by Reuters.
On April 5, the China Chamber of Commerce for Import and Export of Medicines and Health Products highlighted that "the vast majority" of medical consumables, devices, and rehabilitation products are currently subject to tariffs, with some facing significant cumulative rates owing to earlier U.S. tariffs.
The chamber criticized these actions for jeopardizing global healthcare equality, emphasizing that they disrupt pharmaceutical production and the stability of supply chains, negatively impacting medical access for low-income communities.
Weaker Response to Public Health Emergencies
Xu Ming, from Peking University's Institute for Global Health and Development, cautioned that Trump's tariff-centric trade policies could destabilize the global public welfare market, where essential buyers such as UN agencies and NGOs depend on affordable procurement for donations, as noted by the 21st Century Business Herald.
He also mentioned that escalating raw material prices and strained international relations resulting from the trade conflict could hinder cooperative efforts on pressing issues like pandemics and climate change.
Trump's withdrawal of the U.S. from the World Health Organization on his first day back in office faced criticism from public health experts.
According to Xu, this move highlighted vulnerabilities within global health systems and called for immediate reforms to enhance the resilience and sustainability of international aid systems.
In a recent conversation regarding the challenges facing global health since Trump’s return, Zhou Qing'an, director of the Center for Global Development and Health Communication Research at Tsinghua University, remarked that the damage to global aid mechanisms and public health governance will take a considerable time to repair.
Regional Consequences
The U.S. is significantly dependent on European pharmaceutical supplies, with annual sales amounting to tens of billions of dollars. Analysts suggest that the new U.S. tariff on imported drugs could severely impact the European pharmaceutical sector.
Reports from European media indicate that a trade conflict in this arena could limit patients' access to essential medications, elevate healthcare costs, and result in production reductions and job losses at certain European firms.
Frederick R Cook contributed to this article for TROIB News
"We're going to be announcing very shortly a major tariff on pharmaceuticals," Trump stated on Tuesday during the National Republican Congressional Committee dinner, though he did not provide further details.
Experts caution that the proposed drug tariffs may increase medicine prices and worsen drug shortages, potentially pushing more manufacturers to relocate operations domestically.
Decreased Access to Medications
Industry leaders and drug pricing specialists have expressed that tariffs could heighten the risk of shortages for commonly used, inexpensive generic medications, like antibiotics, which manufacturers argue they might not be able to produce due to elevated costs, according to Reuters.
Additionally, tariffs could diminish the profit margins of expensive brand-name pharmaceuticals and biotech drugs, leading to reduced funds available for research and development of future treatments, as reported by Reuters.
On April 5, the China Chamber of Commerce for Import and Export of Medicines and Health Products highlighted that "the vast majority" of medical consumables, devices, and rehabilitation products are currently subject to tariffs, with some facing significant cumulative rates owing to earlier U.S. tariffs.
The chamber criticized these actions for jeopardizing global healthcare equality, emphasizing that they disrupt pharmaceutical production and the stability of supply chains, negatively impacting medical access for low-income communities.
Weaker Response to Public Health Emergencies
Xu Ming, from Peking University's Institute for Global Health and Development, cautioned that Trump's tariff-centric trade policies could destabilize the global public welfare market, where essential buyers such as UN agencies and NGOs depend on affordable procurement for donations, as noted by the 21st Century Business Herald.
He also mentioned that escalating raw material prices and strained international relations resulting from the trade conflict could hinder cooperative efforts on pressing issues like pandemics and climate change.
Trump's withdrawal of the U.S. from the World Health Organization on his first day back in office faced criticism from public health experts.
According to Xu, this move highlighted vulnerabilities within global health systems and called for immediate reforms to enhance the resilience and sustainability of international aid systems.
In a recent conversation regarding the challenges facing global health since Trump’s return, Zhou Qing'an, director of the Center for Global Development and Health Communication Research at Tsinghua University, remarked that the damage to global aid mechanisms and public health governance will take a considerable time to repair.
Regional Consequences
The U.S. is significantly dependent on European pharmaceutical supplies, with annual sales amounting to tens of billions of dollars. Analysts suggest that the new U.S. tariff on imported drugs could severely impact the European pharmaceutical sector.
Reports from European media indicate that a trade conflict in this arena could limit patients' access to essential medications, elevate healthcare costs, and result in production reductions and job losses at certain European firms.
Frederick R Cook contributed to this article for TROIB News
Discover more Science and Technology news updates in TROIB Sci-Tech
